"Okay, Richard, I think we're here, Scott must have told you before, so I won't go around in circles, so as not to waste everyone's time. Pen Fun Pavilion www.biquge.info can you tell us a little bit about your usual work at Dularic? What are you mainly responsible for? I heard Scott say, you're mainly responsible for R&D, so what drugs have you all developed? ”

Jin Muchen asked Richard with a smile, and I don't know why, this young Chinese looks less than thirty years old, but sitting in front of him, Richard can actually feel the kind of temperament that he exudes without anger and self-authority.

has been in the workplace for many years, of course Richard knows what kind of person will have such an momentum, and it must be the kind of person who has been in a high position for a long time to naturally have such an aura.

And when facing such people, you'd better be careful, because you don't know that if you don't say that sentence well, these people will be unhappy, and once these people are unhappy, the consequences will often be serious.

What's more, his friend Scott has repeatedly introduced to him that these two people have a lot of backgrounds, and if he can perform well in front of them this time, then he may not have to go to the West Coast to work again, and even move his family to China.

In the past, Richard may not have been willing to leave the United States, and even more reluctant to go to China, but in the current market environment, going to China may be a very good choice, after all, being able to go to China means that his position can be promoted, and his salary will definitely rise, which is very important to him, after all, behind him, there is still a large family to support.

"Well, Mr. Jin, hello Mr. Wang, I'm going to introduce myself formally, my name is Richard. Torrey, a native of San Francisco, majored in pharmacology at Harvard University. After graduating, I went back to the West Coast and have been working for the company since the very beginning, and now I'm the head of the broad-spectrum antimicrobial department at Dularic, where I've been in for five years, and if you ask me, is there any new R&D in this company... I'm sorry for this... ”

When he said this, Richard paused helplessly and smiled bitterly, and then continued: "The experience of Dularic, perhaps you should all know, was acquired by Amgen a few years ago, but since it was acquired by Amgen. This company has changed its taste, in the past, this company was still quite enterprising, and it had great ambitions and ambitions in the research of new drugs, but since it was controlled by Amgen, this company has no ambition, because there are differences in the direction of business, and the company's annual scientific research funds are limited. The original market in the San Francisco area has been gradually encroached upon by other large pharmaceutical companies. So over the years, I tell the truth, there is no results at all, I, the director of the research department, to put it bluntly, is a blank title, and the main work I am doing now is not research and development at all, but to study and understand, how to make a good copy drug. When other companies' patent protection drugs expire, we must study and understand how people produce them and then copy them, and put such replica drugs into the market as soon as possible. . . ”

This Richard is really honest and direct enough, as soon as he said this, Jin Muchen and Wang Xueming couldn't help but look down on this guy even more, in today's society, especially old fritters in the workplace like him, there are not many people who are so honest.

And what made Jin Muchen and Wang Xueming even happier was that listening to Richard's tone, he seemed to be not very satisfied with Amgen's strategy.

This is a good thing for Jin Muchen and Wang Xueming, after all, the main purpose of their visit to San Francisco this time is to poach, if there are still many people in this company who are dissatisfied with Amgen like Richard, it will be very conducive to their work of digging up the wall.

"So how is your business? Forehead... I may be a bit presumptuous to ask, but I hope you don't mind, we really want to know, what is the level of your Dularic company in terms of generic drugs? How much difference can your generic drug be from the original drug? And what type of broad-spectrum antibiotics are you targeting? ”

Jin Muchen asked Richard again, this question is also very critical, because these people they want to dig up are mainly to produce these antibiotics.

Because many broad-spectrum antibiotics in China have basically entered the second generation, in the eighties of the last century, when domestic antibiotics were not widely used, at that time, the main antibiotics used in China's domestic pharmaceutical market were oxytetracycline, penicillin, erythromycin, tetracycline and other antibiotics.

However, after entering the new century, with the abuse of various antibiotics, the germs in China's patient groups have developed very strong drug resistance, and China has also begun to introduce foreign second-generation antibiotics.

And this antibiotic, including azithromycin, roxithromycin, until now the pioneer, that is, our common cephalica antibiotics on the market.

In particular, there are many different types of antibiotics derived from this type of antibiotic, and such antibiotics are the most widely used and most effective broad-spectrum antibiotics in the domestic pharmaceutical market.

Such drugs have basically passed the patent protection period in the world, and many domestic pharmaceutical factories can produce such antibiotics, but here is also the place where we have the biggest gap with the world.

For the same antibiotic, even if it is the most technologically advanced and largest state-owned pharmaceutical factory producing the same antibiotic, the efficacy of the cephalica series of antibiotics can barely reach about 70% of the same type of antibiotics abroad.

And this 30% gap makes the price difference between domestic cephalic antibiotics and imported cephalica antibiotics dozens of times, and some antibiotics dedicated to certain types of special surgeries, and even the price gap can exceed hundreds of times.

And this part of the price difference blank is also what Jin Muchen and Wang Xueming are concerned about, if they can build such a pharmaceutical factory in China, which can produce antibiotics with similar efficacy to foreign pharmaceutical factories, then when they promote it in China, coupled with Wang Xueming's off-site background, it will be much easier.

The pharmaceutical company becomes bigger and stronger, and it is completely just around the corner.

And the key to making such antibiotics with the same efficacy as those produced by foreign pharmaceutical factories lies in experienced engineers, pharmacists, and to put it bluntly, people like Richard.

It is precisely because of this that Jin Muchen will go straight to the point and ask such a question.

And his question happened to scratch Richard's itch, he has been working in Dularic for more than ten years, and he has not done real research and development a few times, but he can definitely do it with ease when making replication drugs.

And he has a legacy in this industry, because the people of their family have been working in this Dularic company for several generations.

"Let me tell you, Mr. Kim, our family has been working in this Dularic Company since my grandfather, and this Dularic Company was established just after the end of World War II. At that time, they specialized in the production of replication drugs, and my grandfather was the director of the technical department of this company at that time, and it can be said that he was very virtuous in terms of the technology of replication drugs, and later this position was passed on to my father, and then to me. Therefore, in the field of replication drugs, our family is very experienced, and now I am not exaggerating to say that as long as it is a drug on the market that has passed the patent protection period, we can do it, unless some drugs require the use of special technical means and tools. But there is nothing I can't make for ordinary drugs, and I dare to guarantee that the replica drugs we produce can almost be 100% the same as the original drugs on the market, and even some drugs have better efficacy than the original version. This is also the main reason why Dularic has been able to stand in the San Francisco area since the 80s of the last century, and we have a lot of hospitals in the San Francisco area, even the Los Angeles area, and even St. Jones, where many hospitals use our drugs. Of course, this is also the main reason why Amgen was willing to spend a lot of money to buy our company. But I just don't understand, what do those Amgen leaders think? In order to acquire our company, they spent more than a billion yuan, but in the end, they ruined our company in vain. ”

As soon as it comes to the field of replication medicine, this Richard has come to the spirit, their family has been making replication medicine, but it has been passed down for several generations, and there are even many unique small crafts, which is also the main reason why their family can be in charge of the replication medicine department of Dularic for three generations.

And what he said is not an exaggeration, after the drugs copied in the hands of their families, the efficacy is really good, some are not only not worse than the original drugs, but even better than the original drugs.

It's a pity that in the end, these were corrupted by the leaders of Amgen, which also made him resentful of Amgen.

And Jin Muchen and Wang Xueming listened to it is hehe, more than a billion dollars, for you Duraric, it is indeed not a little, but for Amgen, it is just a drop in the bucket, for the future development of the company, they throw more than a billion into the water, listen to the sound, it is not a big deal at all, this is the gap! (To be continued.) )